Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Endometrioid Stromal Sarcoma, Recurrent Uterine Corpus Carcinoma
Conditions
Brief summary
This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer. Trebananib may stop the growth of endometrial cancer by blocking blood flow to the tumor.
Detailed description
PRIMARY OBJECTIVES: I. To estimate the proportion of patients with persistent or recurrent endometrial cancer, who survive progression-free for at least 6 months and the proportion of patients who have objective tumor response (complete or partial), treated with AMG 386 (trebananib). II. To determine the nature and degree of toxicity of AMG 386 in this cohort of patients. SECONDARY OBJECTIVES: I. To estimate the progression-free survival (PFS) and overall survival (OS) of patients with persistent or recurrent endometrial cancer treated with AMG 386. OUTLINE: Patients receive trebananib intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Interventions
BIOLOGICALTrebananib
Given IV
Sponsors
National Cancer Institute (NCI)
Gynecologic Oncology Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have recurrent or persistent endometrial carcinoma, which is refractory to curative therapy or established treatments; histologic confirmation of the original primary tumor is required; stained slides to document the primary tumor as well as recurrent/persistent disease (if documented by histology or cytology) are required * Patients with the following histologic epithelial cell types are eligible: * Endometrioid adenocarcinoma * Serous adenocarcinoma * Undifferentiated carcinoma * Clear cell adenocarcinoma * Mixed epithelial carcinoma * Adenocarcinoma not otherwise specified (N.O.S.) * Mucinous adenocarcinoma * Squamous cell carcinoma * Transitional cell carcinoma * All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be \>= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or \>= 20 mm when measured by chest x-ray; lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI * Patients must have at least one target lesion to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as 'non-target lesions unless progression is documented or a biopsy is obtained to confirm persistence \>= 90 days following completion of radiation therapy * Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG) protocol, if one exists; in general, this would refer to any active GOG phase III or Rare Tumor protocol for the same patient population * Patients who have received one prior chemotherapy regimen must have a GOG performance status of 0, 1, or 2; patients who have received two prior chemotherapy regimens must have a GOG performance status of 0 or 1 * Recovery from effects of recent surgery, radiotherapy, or chemotherapy * Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection \[UTI\]) * Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration * Any other prior therapy directed at the malignant tumor, including chemotherapy and immunologic agents, must be discontinued at least three weeks prior to registration * Any prior radiation therapy must be completed at least 4 weeks prior to registration * Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a chemotherapy regimen * Patients are allowed to receive, but are not required to receive, one additional cytotoxic regimen for management of recurrent or persistent disease * Patients must have NOT received any non-cytotoxic (biologic or targeted) agents as part of their primary treatment or for management of recurrent or persistent disease * Non-cytotoxic (biologic or targeted) agents include (but are not limited to) monoclonal antibodies, cytokines, and small-molecule inhibitors of signal transduction * Prior hormonal therapy is allowed; there is no limit on the number of prior hormonal therapies allowed * Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl * Platelets greater than or equal to 100,000/mcl * Hemoglobin level \>= 9.0 g/dL * Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN) or a creatinine clearance \>= 60 ml/m\^2 * Bilirubin less than or equal to 1.5 x ULN * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN * Alkaline phosphatase less than or equal to 2.5 x ULN * Neuropathy (sensory and motor) less than or equal to grade 1 * Prothrombin time (PT) such that international normalized ratio (INR) is =\< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =\< 1.5 x ULN * Albumin \>= 2.8 mg/dL * Patients must have a urine protein of =\< 1 on dipstick; if dipstick is 2+ or higher, 24-hour urine protein must be obtained and should be \< 1 g for patient to be eligible * Patients must have signed an approved informed consent and authorization permitting release of personal health information * Patients of child bearing potential must agree to use an accepted and effective non-hormonal method of contraception i.e., double barrier method (e.g. condom plus diaphragm) from the time of signing the informed consent through 6 months after last dose of study drug
Exclusion criteria
* Patients who are currently or have been previously treated with trebananib, or other molecules that inhibit the angiopoietins or Tie2 receptor * Patient with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy * Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease * Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease * Patients who are pregnant or nursing * Patients with symptoms of partial or complete bowel obstruction; recent (within 6 months) history of fistula, intraabdominal abscess or bowel perforation; subjects requiring total parenteral nutrition or parenteral hydration * Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including brain tumor, seizures not controlled with standard medical therapy or any brain metastases * Patients with clinically significant cardiovascular disease; this includes: * Myocardial infarction or unstable angina within 12 months of the first date of study treatment * New York Heart Association (NYHA) Class II or greater congestive heart failure * History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication) * Grade 2 or greater peripheral vascular disease * Cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of study treatment * History of arterial ischemia or thrombus * Patients with uncontrolled hypertension defined as systolic \> 150 mm Hg or diastolic \> 90 mm Hg; the use of anti-hypertensive medications to control hypertension is permitted * Patients with significant bleeding within 6 months of enrollment or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels * Patients who have undergone major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of study treatment or who have major surgical procedure anticipated during the course of the study * Patients who have undergone minor surgical procedures within 7 days of the first date of study treatment * Paracentesis and thoracentesis are permitted prior to and while on study at the discretion of the investigator and as clinically indicated * Patients treated with immune modulators such as systemic cyclosporine or tacrolimus within 30 days prior to enrollment * Patients with serious non-healing wound, ulcer (including gastrointestinal), or bone fracture * Patients with known human immunodeficiency virus (HIV), hepatitis C or chronic or active hepatitis B * Patients with any condition which, in the investigator's opinion, makes the patient unsuitable for study participation * Patients not available for follow-up assessments * Patients with known sensitivity to any of the products to be administered during dosing * Patients with history of allergic reactions to bacterially produced proteins * Patients with a history of venous or arterial thromboembolism within 12 months prior to enrollment/randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival > 6 Months | At 6 months | Whether or not the patient survived progression-free for at least 6 months. |
| Objective Tumor Response (Complete or Partial Response) | Up to 5 years | Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
| Adverse Events as Assessed by NCI CTCAE v 4.0 | Up to 5 years | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | From study entry to death or last contact, up to 5 years | The observed length of life from entry into the study to death or the date of last contact. |
| Progression-free Survival | Patients whose disease can be evaluated by physical exam, progression was assessed prior to each cycle. CT or MRI if used to follow leasion for measurable disease, up to 5 years | The time from entry until disease progression, death, or date of last contact. Endpoints are progression or death. Patients who are not observed with an endpoint are censored. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Countries
United States
Participant flow
Recruitment details
GOG 0229L accrued 35 patients from June 2011 to August 2012. 32 of these patients were eligible.
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Trebananib) Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Trebananib: Given IV | 32 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Ineligible | 2 |
| Overall Study | Never treated | 1 |
Baseline characteristics
| Characteristic | Treatment (Trebananib) |
|---|---|
| Age, Customized 40 - 49 years | 1 Participants |
| Age, Customized 50 - 59 years | 6 Participants |
| Age, Customized 60 - 69 years | 11 Participants |
| Age, Customized 70 - 79 years | 14 Participants |
| Sex: Female, Male Female | 32 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 31 / 32 |
| serious Total, serious adverse events | 14 / 32 |
Outcome results
Primary
Adverse Events as Assessed by NCI CTCAE v 4.0
Time frame: Up to 5 years
Population: Eligible and evaluable patients
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Abdominal Pain | 20 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Cough | 24 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anemia | 15 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Thromboembolic Event | 28 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Nausea | 20 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Dyspnea | 25 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Bloating | 28 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyponatremia | 24 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Constipation | 16 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Edema Limbs | 21 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypertension | 20 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Peripheral Sensory Neuropathy | 22 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Vomiting | 25 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Diarrhea | 24 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypoalbuminemia | 24 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyperglycemia | 24 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Lymphedema | 28 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Fatigue | 10 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anorexia | 22 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Localized Edema | 29 Participants |
| Treatment (Trebananib) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Ascites | 27 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Abdominal Pain | 1 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyperglycemia | 6 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Peripheral Sensory Neuropathy | 10 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Thromboembolic Event | 0 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Cough | 7 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Diarrhea | 6 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Lymphedema | 1 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Fatigue | 11 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Bloating | 1 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anemia | 15 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Vomiting | 2 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Constipation | 10 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Localized Edema | 3 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypertension | 1 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Dyspnea | 4 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Nausea | 6 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Ascites | 0 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypoalbuminemia | 3 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Edema Limbs | 4 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyponatremia | 5 Participants |
| Grade 1 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anorexia | 6 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anorexia | 3 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Nausea | 2 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Cough | 1 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypoalbuminemia | 3 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Diarrhea | 2 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Bloating | 3 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyperglycemia | 2 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Abdominal Pain | 3 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Fatigue | 9 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Ascites | 2 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyponatremia | 0 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Thromboembolic Event | 2 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Peripheral Sensory Neuropathy | 0 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Dyspnea | 1 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Constipation | 6 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Edema Limbs | 5 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypertension | 7 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Vomiting | 3 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Lymphedema | 1 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Localized Edema | 0 Participants |
| Grade 2 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anemia | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Vomiting | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Ascites | 3 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Lymphedema | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Thromboembolic Event | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Fatigue | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anemia | 0 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Constipation | 0 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypertension | 4 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Nausea | 4 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Abdominal Pain | 8 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Edema Limbs | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anorexia | 1 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Peripheral Sensory Neuropathy | 0 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Cough | 0 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Diarrhea | 0 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyperglycemia | 0 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyponatremia | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypoalbuminemia | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Dyspnea | 2 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Bloating | 0 Participants |
| Grade 3 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Localized Edema | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Dyspnea | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Abdominal Pain | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Constipation | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Edema Limbs | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anemia | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Nausea | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Vomiting | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Ascites | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Fatigue | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Localized Edema | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Bloating | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypoalbuminemia | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyperglycemia | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Thromboembolic Event | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anorexia | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Cough | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypertension | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyponatremia | 1 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Diarrhea | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Lymphedema | 0 Participants |
| Grade 4 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Peripheral Sensory Neuropathy | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Vomiting | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyperglycemia | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Edema Limbs | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Abdominal Pain | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Ascites | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hyponatremia | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Nausea | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypoalbuminemia | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Hypertension | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Constipation | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Localized Edema | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Dyspnea | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anemia | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Anorexia | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Fatigue | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Bloating | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Thromboembolic Event | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Cough | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Peripheral Sensory Neuropathy | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Lymphedema | 0 Participants |
| Grade 5 (CTCAE v 4.0) | Adverse Events as Assessed by NCI CTCAE v 4.0 | Diarrhea | 0 Participants |
Primary
Objective Tumor Response (Complete or Partial Response)
Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 5 years
Population: Eligible and treated patients.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Trebananib) | Objective Tumor Response (Complete or Partial Response) | 3.1 percentage of participants |
Primary
Progression-free Survival > 6 Months
Whether or not the patient survived progression-free for at least 6 months.
Time frame: At 6 months
Population: Eligible and treated patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Trebananib) | Progression-free Survival > 6 Months | 18.8 percentage of participants |
Secondary
Overall Survival
The observed length of life from entry into the study to death or the date of last contact.
Time frame: From study entry to death or last contact, up to 5 years
Population: Eligible and treated patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Trebananib) | Overall Survival | 6.6 Months |
Secondary
Progression-free Survival
The time from entry until disease progression, death, or date of last contact. Endpoints are progression or death. Patients who are not observed with an endpoint are censored. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Patients whose disease can be evaluated by physical exam, progression was assessed prior to each cycle. CT or MRI if used to follow leasion for measurable disease, up to 5 years
Population: Eligible and treated patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Trebananib) | Progression-free Survival | 2.0 Months |